1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Biosynex SA

Biosynex SA

0.82
EUR
+0.01
(+0.74%)
10.69MMarket Cap
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.2
2.09
1.31
2.76
2.76
2.82
3.18
14.26
30.62
15.86
7.17
9.41
6.59
- -
Basic EPS, GAAP
-1.16
-0.78
-0.05
-0.01
0.03
0.05
0.1
2.91
8.32
1.26
-2.85
-4.03
-4.03
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
2.93
8.79
0.4
-0.74
-0.94
-0.41
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.65
- -
- -
- -
- -
Book Value per Share
2.61
1.77
2.81
2.49
2.61
2.65
2.76
5.98
13.43
13.09
9.84
6.37
1.9
1.9
Tangible Book Value per Share
2.29
1.27
1.38
-0.04
0.35
0.41
0.12
3.17
9.26
6.1
-0.55
-2.56
-2.1
-2.1
Basic Weighted Avg Shares
2
2
8
10
11
11
11
11
12
12
13
11
14
19
Sales/Revenue/Turnover
2
4
10
27
31
31
35
154
383
197
93
101
95
- -
Operating Margin (%)
-54.35
-16.92
-6.19
2.96
3.07
1.19
4.59
29.69
36.89
17.83
-40.23
-35.91
-66.54
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
7
2
21
13
21
53
- -
Net Income, GAAP
-2
-2
- -
- -
- -
1
1
31
104
16
-37
-43
-58
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
10.7
27.38
23.59
28.76
- -
- -
- -
- -
Profit Margin (%)
-96.51
-37.55
-3.69
-0.44
1.03
1.74
3.12
20.38
27.19
7.96
-39.74
-42.83
-61.16
- -
Working Capital
3
2
2
7
10
9
10
44
137
127
57
27
27
27
LT Debt
2
2
3
7
6
5
10
16
35
52
66
62
61
61
Total Equity
4
3
21
24
29
29
31
66
168
167
124
80
35
35
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
3.7
47.47
66.36
12.28
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
3.33
51.56
73.16
7.59
- -
- -
- -
- -
Return on Common Equity (%)
-38.51
-41.3
-2.96
-0.53
1.18
1.87
3.67
64.8
88.86
9.48
-25.75
-42.26
-100.8
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
1
LT Borrowings
62
62
61
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
18
18
Market Capitalization
15
22
11

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
64
62
56
Cash, Cash Equivalents & STI
10
10
8
Accounts Receivable, Net
7
8
8
Inventories
33
26
23
Total Current Liabilities
37
26
29
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.19%
7.05%
-56.58%
Free Cash Flow
- -
-36.11%
-41.81%
Net Income, GAAP
236.42%
-27.55%
34.36%
Sales/Revenue/Turnover
58.95%
10.03%
-5.9%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
93
2024
- -
- -
101
2025
- -
- -
95

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-2.85
2024
- -
- -
-4.03
2025
- -
- -
-4.03

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Larry Abensur
Full Time Employees
408
Sector
Health technology
Industry
Medical specialties
Address
22 Boulevard Sébastien Brant Illkirch-Graffenstaden GE France 67400
IPO Date
Mar 21, 2011
Website
biosynex.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Biosynex SA designs, manufactures and distributes rapid diagnostic tests (RDTs), point-of-care (POC) solutions, molecular biology assays and self-tests for in vitro diagnostics targeting healthcare professionals and consumers; its core portfolio encompasses tests for infectious diseases including bacteriology, parasitology, virology, mycology and COVID-19, women's health products for pregnancy, fertility and sexually transmitted infections, emergency markers, autoimmunity, biochemistry, oncology and tropical diseases such as malaria and tetanus, alongside instruments and immunoblots like Amnioquick, Immunoquick Malaria Falciparum, Immunoquick Elifa HSV IGG and Immunoquick Filtration CELIAC IgA; the company operates through subsidiaries including Chembio Diagnostics, ProciseDx for therapeutic drug monitoring, Medkoncept AS and distribution partners like Fumouze Diagnostics and SR2B. Founded in 2005 and headquartered at 22 Boulevard Sébastien Brant in Illkirch-Graffenstaden, France, Biosynex serves pharmacists, laboratories, doctors, hospitals and pharmacies across more than 90 countries with a focus on screening, diagnosis, prevention and patient care in resource-limited settings. Recent developments include a successful capital increase in February 2025, acceleration of group reorganization announced with 2024 annual results in April 2025 showing revenue growth from exports, FDA breakthrough device designation in June and July 2025 for key products, first-half 2025 revenue of 50.8 million euros reported in July 2025 despite a 6% decline, and initiation of safeguard proceedings in September 2025 to restructure operations alongside earlier acquisitions of ProciseDx in 2023, Chembio Diagnostics in 2023, a 75% stake in Medkoncept AS in January 2023 and Parakito in 2022.